AgomAb Therapeutics (NASDAQ:AGMB) Shares Gap Up – Should You Buy?

AgomAb Therapeutics NV (NASDAQ:AGMB)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $12.82, but opened at $13.40. AgomAb Therapeutics shares last traded at $14.16, with a volume of 133,752 shares.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AGMB. Wall Street Zen downgraded AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. B. Riley Financial started coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target for the company. Piper Sandler started coverage on shares of AgomAb Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $60.00 target price on the stock. HC Wainwright started coverage on AgomAb Therapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $35.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an “overweight” rating for the company. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.50.

AgomAb Therapeutics Trading Up 1.9%

The firm has a fifty day moving average price of $13.10.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. Analysts expect that AgomAb Therapeutics NV will post -1.71 EPS for the current fiscal year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.